Pharmaceutical

Genentech signs nanoparticle deal worth up to $644m with GenEdit

Genentech will utilise GenEdit’s non-viral polymer nanoparticles for gene therapy delivery in autoimmune diseases.

Jan 23, 2024 - 18:00
Genentech signs nanoparticle deal worth up to $644m with GenEdit
Genentech will utilise GenEdit’s non-viral polymer nanoparticles for gene therapy delivery in autoimmune diseases.
Read the original article

Tags:

Previous Article

Newly launched Calluna raises $81m to advance monoclonal antibody pipeline

Next Article

Sanofi signs agreement to acquire Inhibrx for $1.7bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Drug delivery innovations push forth women’s health

Drug delivery innovations push forth women’s health

Apr 11, 2024

STAT+: FDA warns AstraZeneca over misleading promotional materials for a COPD drug

STAT+: FDA warns AstraZeneca over misleading promotiona...

Aug 15, 2023

Osemitamab by Transcenta for Metastatic Biliary Tract C...

Oct 29, 2023